Aventis Pharmaceuticals Inc.

Fernando Camacho

Yulin Chiang

Frank Halley

Gilles Dutruc-Rosset

Yong Mi Choi-Sledeski

Gilles Doerflinger

Gregory Bernard Poli

David Fink

William Arthur Metz, Jr

William Joseph Hurst

Bao-Guo Huang

Joseph T Tsay

Stephen Wayne Harnish

Ann Marie Gelormini

Andrew Giovanni

Joachim E Roehr

Juan Antonio Gamboa

Cesare Mondadori

George A Keesler

Zhengbin Yao

Juan Anotonio Gamboa

The present invention discloses and claims compounds of formula (I) wherein M is N, and K and L are each C with the remaining substituents further defined herein. These compounds are effective as inhibitors of human casein kinase I&#x3b5;, and as such are useful in the treatment of central nervous system diseases and disorders including mood disorders and sleep disorders. Pharmaceutical compositions comprising compounds of formula (I) and methods for the preparation of compounds of formula (I) are also disclosed and claimed.

Substituted 1H-pyrrolo[2,3-c]pyridine-2-carboxamides and related analogs as inhibitors of casein kinase I&#x3b5;

The present invention discloses and claims compounds of formula (I) as inhibitors of human casein kinase IF, and methods of using said compounds of formula (I) for treating central nervous system diseases and disorders including mood disorders and sleep disorders. Pharmaceutical compositions comprising compounds of formula (I) and methods for the preparation of compounds of formula (I) are also disclosed and claimed.

Substituted 1H-pyrrolo[3,2-b, 3,2-c, and 2,3-c]pyridine-2-carboxamides and related analogs as inhibitors of casein kinase lepsilon

The present invention is directed to methods to identify test compounds that alter circadian rhythms of mammals, and more specifically, directed to methods for determining the ability of a test compound to alter hCKI &dgr; and &egr; phosphorylation of a human Period protein. The present invention is also directed to a method for determing the ability of a test compound to selectively alter phosphorylation, interaction with, or alternatively degradation, of one or more human Period proteins relative to its ability to alter phosphorylation, interaction with, or alternatively degradation, of a different human Period protein.

Screening methods for altering circadian rhythms and for human casein kinase I &dgr; and/or &egr; phosphorylation of human clock proteins, period 1, -2 and -3

Growing community of inventors

Union, NJ, United States of America

Fernando Camacho